Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The study will enrol adult female and male patients with BRAF wild-type melanoma and brain
metastases who are not eligible for surgery or radiosurgery and failed prior therapy with
ipilimumab, and patients with BRAF V600 mutation-positive melanoma and brain metastases who
are not eligible for surgery or radiosurgery and who failed prior therapy with a BRAF
inhibitor.